QuickLinks -- Click here to rapidly navigate through this document
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D. C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): July 14, 2004
GENZYME CORPORATION
(Exact name of registrant as specified in its charter)
| Massachusetts (State or other jurisdiction of incorporation or organization) | 0-14680 (Commission file number) | 06-1047163 (IRS employer identification number) | ||
500 Kendall Street, Cambridge, Massachusetts 02142 (Address of Principal Executive Offices) (Zip Code) | ||||
Registrant's telephone number, including area code:
(617) 252-7500
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits
- (c)
- Exhibits
- 99.1
- Press Release of Genzyme Corporation dated July 14, 2004.
Item 12. Results of Operations and Financial Condition
On July 14, 2004, Genzyme Corporation issued a press release relating to its results of operations and financial condition for the three month period ended June 30, 2004. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.
The press release includes certain non-GAAP financial measures that involve adjustments to GAAP figures. Genzyme believes that these non-GAAP financial measures, when considered together with the GAAP figures, can enhance an overall understanding of Genzyme's past financial performance and its prospects for the future. The non-GAAP financial measures are included with the intent of providing both management and investors with a more complete understanding of underlying operational results and trends. In addition, these non-GAAP financial measures are among the primary indicators Genzyme management uses for planning and forecasting purposes. These non-GAAP financial measures are not intended to be considered in isolation or as a substitute for GAAP figures.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| GENZYME CORPORATION | |||
Dated: July 14, 2004 | By: | /s/ MICHAEL S. WYZGA Michael S. Wyzga Executive Vice President, Finance; Chief Financial Officer; and Chief Accounting Officer | |
| Exhibit No. | Description | |
|---|---|---|
| 99.1 | Press Release of Genzyme Corporation dated July 14, 2004 |
- Item 7. Financial Statements, Pro Forma Financial Information and Exhibits
Item 12. Results of Operations and Financial Condition
INDEX TO EXHIBITS